COX-2 specific inhibitors offer improved advantages over traditional NSAIDs

Orthopedics

Volumn 23, Issue 7 SUPPL., 2000, Pages

  Urban, Michael K ^a,b  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; NAPROXEN; PLACEBO; ROFECOXIB;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL FUNCTION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL DISEASE; HUMAN; OSTEOARTHRITIS; PROSTAGLANDIN METABOLISM; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; THROMBOCYTE FUNCTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; CYTOKINES; HUMANS; ISOENZYMES; LACTONES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; PYRAZOLES; QUALITY OF LIFE; SULFONAMIDES; SULFONES;

EID: 0033914562     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998; 41:778-799.
2. Peterson WL, Cryer B. COX-1 sparing NSAIDs - is the enthusiasm justified? JAMA. 1999; 282:1961-1963.
3. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Pharmacol Toxicol. 1998; 38:97-120.
4. Holtzman MJ, Turk J, Sharnick LP. Identification of a pharmacologically distinct prostaglandin H in synthetase in cultured epithelial cells. J Biol Chem. 1992; 267:21438-21445.
5. Gibb W, Sun M. Localization of prostaglandin H synthetase type 2 protein and mRNA in term human fetal membranes and deciduas. J Endocrinol. 1996; 150:497-503.
6. Fosslien E. Adverse effects of nonsteroidal anti-inflammatory drugs on the gastrointestinal system. Ann Clin Lab Sci. 1998; 28:67-81.
7. Eberhart CE, Coffey RJ, Radhjka A, Giardiello PM, Ferrenbach S. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994; 107:1183-1188.
8. Singh G. Recent considerations in non steroidal anti-inflammatory drug gastropathy. Am J Med. 1998; Suppl 18:315-385.
9. Cheatum DE, Arvanitakis C, Gumpei M. An endoscopic study of gastroduodenal lesions induced by nonsteroidal anti-inflammatory drugs. Clin Ther. 1999; 21:992-1003.
10. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. JAMA. 1999; 282:1921-1928.
11. Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA. 1999; 282:1929-1933.
12. Breeder CD, Saper CB. Expression of inducible cyclooxygenase mRNA in the mouse brain after systemic administration of bacterial lipopolysaccharide. Brain Res. 1996; 71:64-69.